Accueil   Diary - News   All news SYNAPCELL



The University of Utah has awarded a subcontract to SynapCell as part of the NIH/NINDS Epilepsy Therapy Screening Program (ETSP).



The partnership between SynapCell and the University of Utah will supplement the University’s ongoing Anticonvulsant Drug Development (ADD) Program to test the efficacy of promising anti-epileptic drug candidates.



Read the press release




SynapCell is an innovative biotechnology company focused on Central Nervous System drug discovery. Understanding the brain’s complexity through brain oscillations requires a high level of expertise and allows us to reveal specific biomarkers of its dysfunction in epileptic, cognitive and movement disorders. For over a decade, our mission has been to reveal the therapeutic potential of drug developers’ compounds, therefore providing them with early decision-making capability to maximize their chances of success.